Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.

Pharmacoepidemiology and drug safety - 1 Nov 2010

Tinè Fabio, Graviano Domenico, Giannuoli Gandolfo, Madonia Salvatore, Malizia Giuseppe, Patti Salvatore, Fasola Salvatore, Cottone Mario, D'Amico Gennaro

Abstract excerpt

PURPOSE: Treatment of patients with chronic hepatitis C with alpha-interferon and ribavirin usually produces adverse events within the first 3 months. We aimed to assess safety and predictors of discontinuation or dose modification of these drugs. METHODS: Observational study of 312 patients with predominantly genotype 1 chronic hepatitis C treated openly along 5 years in a clinical practice setting. RESULTS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Incidence

Share to Interferon-alpha

Share to Medication Adherence

Share to Ribavirin

Source

Identifiers

PMID: 20848397
DOI: 10.1002/pds.2025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.PMID 20848397Read ↗

Sustained Virological Response After Early Discontinuation of Hepatitis C Treatment.Semantic proximity Read ↗

High rates of early treatment discontinuation in hepatitis C-infected US veterans.Semantic proximity Read ↗

Current therapy for hepatitis C.Semantic proximity Read ↗

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial.Semantic proximity Read ↗

Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.Semantic proximity Read ↗

Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions.Semantic proximity Read ↗

Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies.Semantic proximity Read ↗

Safety of direct antiviral agents in real life.Semantic proximity Read ↗

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).Semantic proximity Read ↗

Treatment failure with new hepatitis C drugs.Semantic proximity Read ↗

Chronic Hepatitis C Treatment with Direct-Acting Antiviral Agents in a Real-Life Setting.Semantic proximity Read ↗

Expert opinion on the treatment of patients with chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.